Latest news with #Insights
Yahoo
6 days ago
- Business
- Yahoo
Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032
The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized treatment approaches. This growth is further supported by the increasing demand for precision diagnostics and customized therapies that leverage AI's capabilities in analyzing complex biological data. Advancements in AI-driven technologies, along with ongoing innovation in product development, are improving the accuracy and efficiency of precision-based interventions. New York, USA, May 28, 2025 (GLOBE NEWSWIRE) -- Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032 | DelveInsight The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized treatment approaches. This growth is further supported by the increasing demand for precision diagnostics and customized therapies that leverage AI's capabilities in analyzing complex biological data. Advancements in AI-driven technologies, along with ongoing innovation in product development, are improving the accuracy and efficiency of precision-based interventions. DelveInsight's AI in Precision Medicine Market Insights report provides the current and forecast market analysis, individual leading AI in precision medicine companies' market shares, challenges, AI in precision medicine market drivers, barriers, trends, and key market AI in precision medicine companies in the market. Key Takeaways from the AI in Precision Medicine Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in precision medicine market during the forecast period. In the product segment of the AI in precision medicine market, the hardware/software category held the largest revenue share in 2024. Notable AI in precision medicine companies such as TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., and several others are currently operating in the AI in precision medicine market. In April 2025, Illumina Inc. and Tempus AI, Inc. partnered to accelerate the clinical adoption of next-generation sequencing tests. By combining Illumina's advanced AI technologies with Tempus's extensive multimodal data platform, the collaboration aims to train genomic algorithms and speed up the use of molecular testing in patient care. In February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic device that uses AI to generate heatmaps to identify small or rare prostatic cancers. In June 2024, a leading medical imaging AI company, received 510(k) clearance from the FDA for CINA-VCF, an AI-powered triage and notification tool designed to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing chest or abdomen CT scans. In March 2024, Bayer and Aignostics entered into a collaboration to advance next-generation precision oncology. Together, they will co-develop a novel target identification platform that utilizes multimodal patient data and cutting-edge AI/ML algorithms to enhance cancer treatment precision. To read more about the latest highlights related to the AI in precision medicine market, get a snapshot of the key highlights entailed in the Global AI in Precision Medicine Market Report AI in Precision Medicine Overview Artificial intelligence (AI) is revolutionizing precision medicine by enabling highly personalized approaches to disease diagnosis, treatment, and prevention. By analyzing vast datasets from genomic sequencing, electronic health records, imaging, and wearable devices, AI algorithms can uncover patterns and biomarkers that are often invisible to human researchers. These insights allow clinicians to identify specific disease subtypes, predict individual patient responses to therapies, and tailor treatments to genetic profiles, thus improving efficacy and reducing adverse effects. In oncology, for instance, AI is helping identify actionable mutations and optimize targeted therapies, bringing more precise interventions to patients. Beyond diagnosis and treatment, AI also plays a crucial role in accelerating drug discovery and development in precision medicine. Machine learning models can predict drug-target interactions, simulate clinical outcomes, and identify suitable patient cohorts for clinical trials, significantly cutting down timelines and costs. Moreover, AI enhances real-time monitoring of patient health through integration with digital health tools, facilitating timely interventions and adaptive treatment strategies. As data grows more complex and voluminous, AI's ability to synthesize, learn, and adapt offers an indispensable advantage in realizing the full potential of precision in Precision Medicine Market Insights North America held the largest share of the AI in precision medicine market from 2025 to 2032. This leading position can be attributed to several key factors, including the increasing prevalence of chronic conditions such as cancer, lifestyle-related illnesses like diabetes, and various infectious diseases. The region also benefits from robust R&D initiatives in AI-driven precision medicine, a well-developed healthcare infrastructure. In addition, major companies in the region are making substantial R&D investments to bring cutting-edge AI-based precision medicine solutions to market. For instance, in April 2024, Prenosis secured FDA De Novo marketing authorization for its Sepsis ImmunoScore™, an AI-powered diagnostic tool that supports precision diagnosis and risk assessment for sepsis. Likewise, in February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an AI-enabled in vitro diagnostic device that generates heatmaps to detect small or rare prostatic cancers, offering a critical diagnostic aid for pathologists. As a result of these combined factors, the AI in precision medicine market is expected to experience significant growth in North America throughout the forecast period. To know more about why North America is leading the market growth in the AI in precision medicine market, get a snapshot of the AI in Precision Medicine Market Outlook AI in Precision Medicine Market Dynamics The AI in precision medicine market is undergoing rapid transformation, driven by the convergence of big data analytics, machine learning, and personalized healthcare. Precision medicine focuses on tailoring medical treatment to the individual characteristics of each patient, and AI enables this by analyzing vast datasets from genomic information to electronic health records to identify patterns, predict outcomes, and guide clinical decisions. This has created significant demand for AI-enabled platforms that can support drug discovery, diagnostics, and treatment planning, especially in oncology, rare diseases, and chronic conditions. Market growth is being accelerated by increasing investments from pharmaceutical companies, biotech startups, and technology giants. These players are leveraging AI to reduce the cost and time of clinical trials, improve target identification, and develop more precise biomarkers. Government initiatives like the U.S. Precision Medicine Initiative and the EU's Digital Health Strategy are also catalyzing adoption by funding R&D and creating regulatory frameworks that support innovation in AI-driven healthcare solutions. As a result, the global market for AI in precision medicine is projected to grow at a strong CAGR through the next decade. Despite these tailwinds, the market faces several challenges. Data privacy and interoperability remain major hurdles, especially given the sensitive nature of health data and the lack of standardized health IT systems across countries and institutions. Moreover, ethical concerns around algorithmic bias, transparency, and patient consent are prompting calls for tighter regulation and governance. Trust in AI systems remains a key barrier to adoption among healthcare professionals, who often require explainable and clinically validated outputs before integrating AI into routine practice. Nevertheless, the competitive landscape is vibrant. Major tech firms are partnering with hospitals and research institutions to advance AI-driven care models. Startups focusing on niche applications, such as AI-powered pathology, genomic interpretation, and personalized oncology treatments, are also attracting significant venture capital. As the ecosystem matures, we can expect increasing consolidation and the emergence of integrated platforms that bridge diagnostics, therapeutics, and decision support, further driving market expansion. Get a sneak peek at the AI in precision medicine market dynamics @ AI in Precision Medicine Market Dynamic Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Precision Medicine Market CAGR ~33% AI in Precision Medicine Market Size by 2032 USD 10.2 Billion Key AI in Precision Medicine Companies TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others AI in Precision Medicine Market Assessment AI in Precision Medicine Market Segmentation AI in Precision Medicine Market Segmentation By Product: Hardware/Software and Services AI in Precision Medicine Market Segmentation By Technology: Deep Learning, Natural Language Processing, and Machine Learning AI in Precision Medicine Market Segmentation By Application: Drug Discovery & Development and Disease Diagnostics AI in Precision Medicine Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others AI in Precision Medicine Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the AI in precision medicine market are set to emerge as the trendsetter explore @ AI in Precision Medicine Companies Table of Contents 1 AI in Precision Medicine Market Report Introduction 2 AI in Precision Medicine Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Precision Medicine Market Key Factors Analysis 6 AI in Precision Medicine Market Porter's Five Forces Analysis 7 AI in Precision Medicine Market Layout 8 AI in Precision Medicine Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the AI in precision medicine market by 2032? Click to get a snapshot of the AI in Precision Medicine Market Trends Related Reports Artificial Intelligence in Drug Commercialization Market Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others. Artificial Intelligence in Clinical Trials Market Artificial Intelligence in Clinical Trials Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in clinical trials companies, including TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others. Artificial Intelligence In Drug Discovery Market Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others. Artificial Intelligence in Medical Imaging Market Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others. Artificial Intelligence in Life Sciences Market Artificial Intelligence in Life Sciences Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in life sciences companies, including IBM Corporation, Atomwise, Inc., Nuance Communications, Inc., NuMedii, Inc., AiCure LLC, APIXIO, Inc., Insilico Medicine, Inc., Enlitic, Inc., Sensely, Inc., Zebra Medical Vision, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679 in to access your portfolio
Associated Press
7 days ago
- Business
- Associated Press
LexCheck 3.0 Delivers Unmatched AI Redlining Power
NEW YORK, May 28, 2025 /PRNewswire/ -- LexCheck, the leading provider of AI-powered contract review solutions, today announced the launch of LexCheck 3.0, the most advanced and comprehensive AI contract review and redlining tool on the market. 'Following the success of January's Insights release, LexCheck 3.0 represents a significant leap forward in redline accuracy, ease-of-use, and enterprise-grade scalability – setting a new industry benchmark,' said Gary Sangha, CEO of LexCheck. Designed to be intuitive, powerful, and lightning-fast, LexCheck 3.0 delivers you precise guidance and redlines directly within Microsoft Word, requiring no changes to your existing workflows. What makes LexCheck 3.0 a true game-changer and superior to any other AI contract review tool is its unmatched ability to deliver precise, context-aware redlines by learning from your past negotiations, adapting to organization-wide preferences, and performing reliably across all contract types, from NDAs to complex commercial agreements. LexCheck 3.0 automatically creates review guidelines based on your actual historical redlines and applies edits to ensure playbook compliance. Leveraging LexCheck's existing capabilities, LexCheck can also flag deviations from your preferred language, even when those deviations weren't previously marked. Additionally, LexCheck 3.0's precedent checker will review counterparty positions against precedents to show whether similar terms have been accepted in the past. Most importantly, LexCheck 3.0 isn't just built for routine or low-risk agreements. It's optimized to handle your high-value, high-complexity contracts – including MSAs, SaaS agreements, construction agreements and stock purchase agreements – with accuracy and depth that far surpasses what other tools can offer. Whether reviewing ten contracts or ten thousand, LexCheck 3.0 scales effortlessly across teams and workflows. With LexCheck 3.0, what's possible in contract review has been redefined: smarter guidance, faster workflows, and legal precision, all powered by AI. About LexCheck LexCheck is the leading provider of AI-powered contract review and negotiation software, trusted by legal and procurement teams worldwide. By combining generative AI with a customizable framework, LexCheck delivers a fast, smart, and precise contract analysis solution. For more information, visit Media Contact Kevin Koplin [email protected] 212-352-8581 View original content to download multimedia: SOURCE LexCheck Inc.
Yahoo
27-05-2025
- Business
- Yahoo
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
PRINCETON, N.J., May 27, 2025--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA to take place on May 27-28, 2025. TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date / Time: May 28, 2025, at 9:00 AM ET Format: Fireside Chat Location: Virtual Webcast Link: here Webcasts from the conferences will also be available on UroGen's Investor Relations website. A replay will be available on the site for approximately 90 days. About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with recurrent low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on X (Twitter), @UroGenPharma. View source version on Contacts INVESTORS: Vincent PerroneSenior Director, Investor 609-460-3588 ext. 1093 MEDIA: Cindy RomanoDirector, Corporate 609-460-3583 ext. 1083 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Oxford Brain Diagnostics initiates dementia diagnostic commercialisation
Oxford Brain Diagnostics (OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by analysing MRI scans. The UK company's cloud-based Cortical Disarray Measurement (CDM) Insights software processes MRI scan data to monitor patient brain changes across multiple stages of life, outputting the data as percentiles of a normative population distribution to provide an "objective, quantifiable measure of neurodegeneration". According to OBD, CDM's assessment of microstructural and macrostructural measurements, as well as cortical thickness, will bring methods of analysis to assist clinicians in the early detection of neurodegeneration currently unavailable on the US market. CDM Insights received a breakthrough device designation from the US Food and Drug Administration (FDA) in 2020 and 510(k) clearance from the agency in January 2025. Intended for use by healthcare practitioners, including neurologists and radiologists, OBD states that the CDM software will be made available to all US healthcare facilities. OBD CEO and co-founder Dr Steven Chance commented: 'Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage. 'These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease.' Spun out from the University of Oxford in 2018, OBD stated that it had reached this stage in its development due to a 2023 funding round led by the London-headquartered Business Growth Fund (BGF). This included additional support from existing investors, including the Oxford Technology & Innovations Fund (OTIF). Dr Chance continued: 'The support from BGF and other investors and partners is enabling us to accelerate the path to the commercialisation of our software tool and bring hope to those millions who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health.' The ability to detect neurodegenerative conditions earlier is an area of rising importance in pharmacology. A recent open-label extension (OLE) study (NCT06424236) of Roche's discontinued Alzheimer's drug, gantenerumab, showed signs that it could prevent the onset of the disease. Data from the OLE published in The Lancet demonstrated that the anti-amyloid drug cut the risk of developing symptoms by 50% for a subgroup of 22 participants who had no cognitive problems at the beginning of the study and who received the drug for an average of eight years. BGF investor Maggie Lau commented: 'The landscape for neurological diagnostics is evolving rapidly, particularly with the arrival of new anti-amyloid Alzheimer's drugs, sharpening the focus on early, accurate diagnosis. 'OBD's technology directly addresses this by enabling timely detection and precise monitoring of neurodegenerative disease.' "Oxford Brain Diagnostics initiates dementia diagnostic commercialisation" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Oxford Brain Diagnostics initiates dementia diagnostic commercialisation
Oxford Brain Diagnostics (OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by analysing MRI scans. The UK company's cloud-based Cortical Disarray Measurement (CDM) Insights software processes MRI scan data to monitor patient brain changes across multiple stages of life, outputting the data as percentiles of a normative population distribution to provide an "objective, quantifiable measure of neurodegeneration". According to OBD, CDM's assessment of microstructural and macrostructural measurements, as well as cortical thickness, will bring methods of analysis to assist clinicians in the early detection of neurodegeneration currently unavailable on the US market. CDM Insights received a breakthrough device designation from the US Food and Drug Administration (FDA) in 2020 and 510(k) clearance from the agency in January 2025. Intended for use by healthcare practitioners, including neurologists and radiologists, OBD states that the CDM software will be made available to all US healthcare facilities. OBD CEO and co-founder Dr Steven Chance commented: 'Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage. 'These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease.' Spun out from the University of Oxford in 2018, OBD stated that it had reached this stage in its development due to a 2023 funding round led by the London-headquartered Business Growth Fund (BGF). This included additional support from existing investors, including the Oxford Technology & Innovations Fund (OTIF). Dr Chance continued: 'The support from BGF and other investors and partners is enabling us to accelerate the path to the commercialisation of our software tool and bring hope to those millions who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health.' The ability to detect neurodegenerative conditions earlier is an area of rising importance in pharmacology. A recent open-label extension (OLE) study (NCT06424236) of Roche's discontinued Alzheimer's drug, gantenerumab, showed signs that it could prevent the onset of the disease. Data from the OLE published in The Lancet demonstrated that the anti-amyloid drug cut the risk of developing symptoms by 50% for a subgroup of 22 participants who had no cognitive problems at the beginning of the study and who received the drug for an average of eight years. BGF investor Maggie Lau commented: 'The landscape for neurological diagnostics is evolving rapidly, particularly with the arrival of new anti-amyloid Alzheimer's drugs, sharpening the focus on early, accurate diagnosis. 'OBD's technology directly addresses this by enabling timely detection and precise monitoring of neurodegenerative disease.' "Oxford Brain Diagnostics initiates dementia diagnostic commercialisation" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
